{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T04:55:03Z","timestamp":1764996903847,"version":"3.44.0"},"reference-count":74,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1053\/j.seminhematol.2010.11.001","type":"journal-article","created":{"date-parts":[[2011,1,12]],"date-time":"2011-01-12T05:43:28Z","timestamp":1294811008000},"page":"55-65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Bone Disease From Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma: Pathogenesis, Interventions, and Future Opportunities"],"prefix":"10.1053","volume":"48","author":[{"given":"Alex R.","family":"Minter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haley","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brendan M.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ola","family":"Landgren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2010.11.001_bib1","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.beha.2005.01.008","article-title":"Multiple myeloma: clinical features and indications for therapy","volume":"19","author":"Dispenzieri","year":"2005","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib2","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1038\/leu.2009.134","article-title":"Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic\/racial groups: support for genetic factors in pathogenesis","volume":"23","author":"Landgren","year":"2009","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib3","first-page":"192","article-title":"Pathogenesis of myeloma bone disease","volume":"32","author":"Roodman","year":"2005","journal-title":"Blood Cells Mol Dis"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib4","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/cncr.22991","article-title":"Pathologic fractures correlate with reduced survival in patients with malignant bone disease","volume":"110","author":"Saad","year":"2007","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib5","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1359\/JBMR.041131","article-title":"Fracture risk with multiple myeloma: a population-based study","volume":"20","author":"Melton","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib6","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.exphem.2004.03.015","article-title":"New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NG-kappaB ligand (RANKL)","volume":"32","author":"Giuliani","year":"2005","journal-title":"Exp Hematol"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3109\/10428190903503438","article-title":"Osteoblastogenesis and tumor growth in myeloma","volume":"51","author":"Yaccoby","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib8","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1172\/JCI115305","article-title":"Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma","volume":"88","author":"Bataille","year":"1991","journal-title":"J Clin Invest"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib9","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1365-2141.1982.tb03936.x","article-title":"Quantitative histology of myeloma-induced bone changes","volume":"52","author":"Valentin","year":"1982","journal-title":"Br J Hematol"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib10","first-page":"3047","article-title":"Serum levels of carboxy-terminal telopeptide of type-I collagen are elevated in patients with multiple myeloma showing skeletal manifestations in magnetic resonance imaging but lacking bone lesions in conventional radiography","volume":"9","author":"Jakob","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib11","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1600-0609.1997.tb00932.x","article-title":"Abnormal bone turnover in monoclonal gammopathy of undetermined significance: analysis of type I collage telopeptide osteocalcin, bone-specific alkaline phosphatase and propeptides of type I and type III procollagens","volume":"58","author":"Vejlgaard","year":"1997","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1034\/j.1600-0609.2002.00505.x","article-title":"Bone resporption parameters [carboxy-terminal telopeptide of type-I collagen (ICTP), amino-terminal collagen type-I telopeptide (NTx), and deoxypyridinoline (Dpd)] in MGUS and multiple myeloma","volume":"69","author":"Jakob","year":"2002","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib13","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0959-8049(97)10133-2","article-title":"Myeloma bone disease","volume":"34","author":"Mundy","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib14","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1182\/blood.V87.11.4762.bloodjournal87114762","article-title":"Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: a prospective study of 87 bone biopsies","volume":"87","author":"Battaille","year":"1996","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib15","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1159\/000162282","article-title":"Prevelance of monoclonal gammopathy of undetermined significance\/myeloma in patients with acute osteoporotic vertebral fractures","volume":"120","author":"Golombick","year":"2008","journal-title":"Acta Heamatol"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib16","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1365-2141.2006.06217.x","article-title":"Lumbar bone mineral density as the major factor determining increased prevalence of vertebral fractures in monoclonal gammopathy of undetermined significance","volume":"134","author":"Pepe","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib17","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1365-2141.2006.06269.x","article-title":"Fracture risk in patents with monoclonal gammopathy of undetermined significance","volume":"135","author":"Gregersen","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib18","doi-asserted-by":"crossref","first-page":"685","DOI":"10.4065\/84.8.685","article-title":"Dissease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17\/398 patients","volume":"84","author":"Bida","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib19","article-title":"Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study","author":"Kristinsson","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib20","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1182\/asheducation-2002.1.214","article-title":"Multiple Myeloma","volume":"2202","author":"Anderson","year":"2002","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib21","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","article-title":"The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma","volume":"349","author":"Tian","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib22","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1634\/stemcells.2005-0220","article-title":"A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma","volume":"24","author":"Gunn","year":"2006","journal-title":"Stem Cells"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib23","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1182\/blood-2007-03-067710","article-title":"Myeloma bone disease and proteasome inhibition therapies","volume":"110","author":"Terpos","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib24","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1302\/0301-620X.71B2.2925748","article-title":"Does myeloma secrete and osteoblast inhibiting factor?","volume":"71","author":"Evans","year":"1989","journal-title":"J Bone Joint Surg Br"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib25","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1359\/jbmr.1999.14.2.256","article-title":"Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice","volume":"14","author":"Hjorth-Hansen","year":"1999","journal-title":"J Bone Miner Res"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib26","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1365-2141.2004.05084.x","article-title":"Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells","volume":"126","author":"Silvestris","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib27","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1096\/fj.05-4329fje","article-title":"A role of TRAIL in killing osteoblasts by myeloma cells","volume":"20","author":"Tinhofer","year":"2006","journal-title":"FASEB J"},{"author":"Roodman","key":"10.1053\/j.seminhematol.2010.11.001_bib28"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib29","doi-asserted-by":"crossref","unstructured":"Karadag A, Oyajobi BO, Apperley JF, Russell RG, Croucher PI. Human myeloma cells promote the production of interleukin-6 by primary human osteoblasts. Br J Haematol. 200;108:383-90.","DOI":"10.1046\/j.1365-2141.2000.01845.x"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib30","first-page":"912","article-title":"Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis inducing ligand\/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells","volume":"63","author":"Shipman","year":"2003","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib31","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood-2006-09-047712","article-title":"Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo","volume":"109","author":"Yaccoby","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib32","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1182\/blood-2006-05-026112","article-title":"Mutiple myeloma bone disease: pathophysiology of osteoblast inhibition","volume":"108","author":"Giuliani","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib33","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1080\/10428190701648281","article-title":"Myeloma cells and bone marrow osteoblast interactions: role in the development of osteolytic lesions in multiple myeloma","volume":"48","author":"Giuliani","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib34","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1210\/en.2004-1343","article-title":"Minireview: transcriptional regulation in development of bone","volume":"146","author":"Kobayashi","year":"2005","journal-title":"Endocrinology"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib35","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/jcb.22403","article-title":"Pathogenesis of myeloma bone disease","volume":"109","author":"Roodman","year":"2010","journal-title":"J Cell Biochem"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib36","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1182\/blood-2004-12-4986","article-title":"Myeloma cells block RUNX2\/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation","volume":"106","author":"Giuliani","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib37","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1182\/blood.V96.5.1953","article-title":"Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast stimulating activity","volume":"96","author":"Michigami","year":"2000","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib38","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0002-9440(10)62556-4","article-title":"Expression of CD56\/neural cell adhesion molecule correlates with the presence of lytic lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation","volume":"160","author":"Ely","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib39","first-page":"76","article-title":"Multiple myeloma and bone disease: pathogenesis and current therapeutic approaches","volume":"14","author":"Papadopoulou","year":"2010","journal-title":"Hippokratia"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib40","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.gene.2004.06.044","article-title":"Wnt signaling in osteblasts and bone diseases","volume":"341","author":"Westendorff","year":"2004","journal-title":"Gene"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib41","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.hoc.2007.08.009","article-title":"Pathophysiology of multiple myeloma bone disease","volume":"21","author":"Lentzch","year":"2007","journal-title":"Hematol Oncol Clin N Am"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib42","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.bone.2008.01.027","article-title":"The pathogenesis of the bone disease of multiple myeloma","volume":"42","author":"Edwards","year":"2008","journal-title":"Bone"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib43","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1182\/blood-2005-03-1080","article-title":"IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma","volume":"106","author":"Ehrlich","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib44","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/blood-2006-07-034884","article-title":"HGF inhibits BMP-induced osteoblastogenesis: possible implications for bone disease of multiple myeloma","volume":"109","author":"Standal","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib45","first-page":"1101","article-title":"Enhancement of osteoblast differentiation by inhibition of TGF-beta signaling suppresses myeloma cell growth and protects from destructive bone lesions","volume":"21","author":"Takeuchi","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib46","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1182\/blood-2004-12-4986","article-title":"Myeloma cells block RUNX2\/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation","volume":"106","author":"Giuliani","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib47","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/leu.2008.336","article-title":"Pathogenesis of myeloma bone disease","volume":"23","author":"Roodman","year":"2009","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib48","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1365-2141.1995.tb05609.x","article-title":"Excessive bone resorption in human plasmacytomas: direct induction by tumour cells in vivo","volume":"90","author":"Bataille","year":"1995","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib49","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/36593","article-title":"A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function","volume":"390","author":"Anderson","year":"1997","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib50","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: A novel secreted protein involved in the regulation of bone density","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib51","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1182\/blood-2002-09-2684","article-title":"RANK ligand and osteoprotegerin in myeloma bone disease","volume":"101","author":"Sezer","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib52","doi-asserted-by":"crossref","first-page":"11581","DOI":"10.1073\/pnas.201394498","article-title":"Multiple myeloma disrupts the TRANCE\/osteoprotegerin cytokine axs to stimulate bone destruction and promote tumor progression","volume":"98","author":"Pearse","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib53","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1182\/blood-2003-02-0380","article-title":"Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for novel prognostic index","volume":"102","author":"Terpos","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib54","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V100.6.2195","article-title":"Role for macrophage inflammatory protein (MIP)-1 alpha and MIP-1 beta in the development of osteolytic lesions in multiple myeloma","volume":"100","author":"Abe","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib55","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1046\/j.1365-2141.2003.04561.x","article-title":"Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma","volume":"123","author":"Terpos","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib56","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1182\/blood.V96.2.671.014k24_671_675","article-title":"Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma","volume":"96","author":"Choi","year":"2000","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib57","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1158\/0008-5472.CAN-04-1687","article-title":"Elevated serum levels of stromal-derived factor-1 alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients","volume":"65","author":"Zannettino","year":"2005","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib58","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1158\/1078-0432.CCR-06-2258","article-title":"Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin","volume":"13","author":"Tanaka","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib59","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2003-11-3839","article-title":"Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion","volume":"104","author":"Abe","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib60","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced myeloma","volume":"334","author":"Berenson","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib61","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1200\/JCO.1998.16.2.593","article-title":"Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events","volume":"16","author":"Berenson","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib62","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib63","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1200\/JCO.2007.12.1269","article-title":"American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma","volume":"25","author":"Kyle","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib64","doi-asserted-by":"crossref","first-page":"908","DOI":"10.6004\/jnccn.2009.0061","article-title":"NCCN clinical practice guidelines in oncology: multiple myeloma","volume":"7","author":"Anderson","year":"2009","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib65","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.4065\/81.8.1047","article-title":"Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma","volume":"81","author":"Lacy","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib66","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/annonc\/mdn796","article-title":"The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European myeloma network","volume":"20","author":"Terpos","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib67","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1365-2141.2006.06230.x","article-title":"Incidenc, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients","volume":"134","author":"Zervas","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib68","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/cncr.23783","article-title":"A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma","volume":"113","author":"Musto","year":"2008","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib69","first-page":"8550","article-title":"Marked improvement in bone mineral density (BMD) for patients (pts) with monoclonal gammopathy of undetermined significance (MGUS) using zoledronic acid (ZOL) [abstract]","volume":"26","author":"Berenson","year":"2008","journal-title":"ASCO Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib70","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.3109\/10428190309178778","article-title":"Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: results of a randomized trial","volume":"44","author":"Musto","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib71","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1200\/JCO.2003.99.248","article-title":"Pamidronate for early-stage, untreated myeloma","volume":"21","author":"Musto","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib72","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1046\/j.1365-2141.2002.03549.x","article-title":"Pamidronate induces bone formation in patients with smouldering or indolent myeloma, with no significant antitumor effect","volume":"118","author":"Martin","year":"2002","journal-title":"Br J Hematol"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib73","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S1470-2045(10)70198-4","article-title":"Effect of pamidronate 30mg versus 90mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomized controlled trial","volume":"11","author":"Gimsing","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminhematol.2010.11.001_bib74","doi-asserted-by":"crossref","first-page":"6270s","DOI":"10.1158\/1078-0432.CCR-06-0845","article-title":"New potential targets for treating myeloma bone disease","volume":"12","author":"Roodman","year":"2006","journal-title":"Clin Cancer Res"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196310001046?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196310001046?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:21:17Z","timestamp":1758522077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196310001046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S0037196310001046"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2010.11.001","relation":{},"ISSN":["0037-1963"],"issn-type":[{"type":"print","value":"0037-1963"}],"subject":[],"published":{"date-parts":[[2011,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bone Disease From Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma: Pathogenesis, Interventions, and Future Opportunities","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2010.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}